<?xml version="1.0" encoding="utf-8"?><rss version="2.0"><channel><title>the Pharmaceutical companies community of South Africa</title><link>http://medical.bizcommunity.com//196/326.html</link><description>South Africa pharmaceutical companies news</description><ttl>15</ttl><category>Pharmaceutical companies news - South Africa</category><image><url>http://www.bizcommunity.com/res/img/11/logo5.gif</url><title>Bizcommunity.com</title><link>http://www.bizcommunity.com/</link></image><language>en-us</language><pubDate>Sun, 22 Nov 2009 11:20:36 +0200</pubDate><item><title>AstraZeneca MHC ranks first in Campbell Belman survey</title><link>http://www.bizcommunity.com/Article/196/326/39680.html</link><description>&lt;p&gt;AstraZeneca has been ranked first by the Funders in the annual Campbell Belman Managed Health Care (MHC) Confidence Predictor/Confidence Development for the eighth consecutive year. The annual survey aims to provide continuous, objective, and empirical feedback on the level of confidence ethical pharmaceutical companies enjoy among the medical profession when compared to their competitors.&lt;br /&gt; &lt;a href="http://www.bizcommunity.com/Article/196/326/39680.html"&gt;Read full story...&lt;/a&gt; | &lt;a href="http://www.bizcommunity.com/SendToFriend.aspx?l=196&amp;c=326&amp;ct=1&amp;ci=39680"&gt;Send to a friend&lt;/a&gt;&lt;/p&gt;</description><guid>http://www.bizcommunity.com/Article/196/326/39680.html</guid><pubDate>Mon, 07 Sep 2009 09:10:00 +0200</pubDate><source>http://www.bizcommunity.com/rss/196/326.html</source></item><item><title>Alcon Laboratories renews contract with X/Procure</title><link>http://www.bizcommunity.com/Article/196/326/39394.html</link><description>&lt;p&gt;&lt;img src="http://mars.bizcommunity.com/c/0908/35702.jpg?r=0" width="53" height="65" align="left"  /&gt;Alcon Laboratories has renewed its advertising contract with Primedia Unlimited's X/procure. The pharmaceutical manufacturer in its latest communication seeks to promote its itchy and watery eye fighter Patanol. The campaign will run for a period of four months, coinciding with the approaching change of seasons.&lt;br /&gt; &lt;a href="http://www.bizcommunity.com/Article/196/326/39394.html"&gt;Read full story...&lt;/a&gt; | &lt;a href="http://www.bizcommunity.com/SendToFriend.aspx?l=196&amp;c=326&amp;ct=1&amp;ci=39394"&gt;Send to a friend&lt;/a&gt;&lt;/p&gt;</description><guid>http://www.bizcommunity.com/Article/196/326/39394.html</guid><pubDate>Fri, 28 Aug 2009 15:18:00 +0200</pubDate><source>http://www.bizcommunity.com/rss/196/326.html</source></item><item><title>ATKA Pharma renews contract with X/procure</title><link>http://www.bizcommunity.com/Article/196/326/36027.html</link><description>&lt;p&gt;&lt;img src="http://mars.bizcommunity.com/c/0905/30543.jpg?r=0" width="65" height="69" align="left"  /&gt;ATKA Pharma has confirmed a one-year deal with the electronic procurement specialist, X/procure. The partnership started with an &amp;quot;Intervention&amp;quot; advertising campaign for its liquid Immunodulator called Biobalance Immunova.&lt;br /&gt; &lt;a href="http://www.bizcommunity.com/Article/196/326/36027.html"&gt;Read full story...&lt;/a&gt; | &lt;a href="http://www.bizcommunity.com/SendToFriend.aspx?l=196&amp;c=326&amp;ct=1&amp;ci=36027"&gt;Send to a friend&lt;/a&gt;&lt;/p&gt;</description><guid>http://www.bizcommunity.com/Article/196/326/36027.html</guid><pubDate>Mon, 18 May 2009 11:42:00 +0200</pubDate><source>http://www.bizcommunity.com/rss/196/326.html</source></item><item><title>bioMerieux forges unique BEE partnership</title><link>http://www.bizcommunity.com/Article/196/326/34390.html</link><description>&lt;p&gt;The partnership is between bioMérieux and Litha Healthcare Holdings&lt;br /&gt; &lt;a href="http://www.bizcommunity.com/Article/196/326/34390.html"&gt;Read full story...&lt;/a&gt; | &lt;a href="http://www.bizcommunity.com/SendToFriend.aspx?l=196&amp;c=326&amp;ct=1&amp;ci=34390"&gt;Send to a friend&lt;/a&gt;&lt;/p&gt;</description><guid>http://www.bizcommunity.com/Article/196/326/34390.html</guid><pubDate>Mon, 30 Mar 2009 10:35:00 +0200</pubDate><source>http://www.bizcommunity.com/rss/196/326.html</source></item><item><title>Austell Laboratories turns four</title><link>http://www.bizcommunity.com/Article/196/326/34078.html</link><description>&lt;p&gt;&lt;img src="http://mars.bizcommunity.com/c/0903/27931.jpg?r=0" width="65" height="43" align="left"  /&gt;Independent, Johannesburg-based pharmaceutical company Austell Laboratories will celebrate its fourth birthday in April 2009. Initially the company was established as Camox Pharmaceuticals in 2000 with an initial focus on tender-based products. In 2005 the company entered the private market and Austell Laboratories (Pty) Ltd was established.&lt;br /&gt; &lt;a href="http://www.bizcommunity.com/Article/196/326/34078.html"&gt;Read full story...&lt;/a&gt; | &lt;a href="http://www.bizcommunity.com/SendToFriend.aspx?l=196&amp;c=326&amp;ct=1&amp;ci=34078"&gt;Send to a friend&lt;/a&gt;&lt;/p&gt;</description><guid>http://www.bizcommunity.com/Article/196/326/34078.html</guid><pubDate>Fri, 20 Mar 2009 11:39:00 +0200</pubDate><source>http://www.bizcommunity.com/rss/196/326.html</source></item><item><title>Fine Healthcare in partnership with Smith and Nephew</title><link>http://www.bizcommunity.com/Article/196/326/33609.html</link><description>&lt;p&gt;Johannesburg, South Africa - 6 March, 2009 - For over 150 years, Smith &amp; Nephew has developed advanced medical devices for healthcare professionals around the world.&lt;br /&gt; &lt;a href="http://www.bizcommunity.com/Article/196/326/33609.html"&gt;Read full story...&lt;/a&gt; | &lt;a href="http://www.bizcommunity.com/SendToFriend.aspx?l=196&amp;c=326&amp;ct=1&amp;ci=33609"&gt;Send to a friend&lt;/a&gt;&lt;/p&gt;</description><guid>http://www.bizcommunity.com/Article/196/326/33609.html</guid><pubDate>Tue, 10 Mar 2009 09:36:00 +0200</pubDate><source>http://www.bizcommunity.com/rss/196/326.html</source></item><item><title>Aspen's interim results</title><link>http://www.bizcommunity.com/Article/196/326/33498.html</link><description>&lt;p&gt;Aspen's offshore operations drive an impressive 91% revenue increase.&lt;br /&gt; &lt;a href="http://www.bizcommunity.com/Article/196/326/33498.html"&gt;Read full story...&lt;/a&gt; | &lt;a href="http://www.bizcommunity.com/SendToFriend.aspx?l=196&amp;c=326&amp;ct=1&amp;ci=33498"&gt;Send to a friend&lt;/a&gt;&lt;/p&gt;</description><guid>http://www.bizcommunity.com/Article/196/326/33498.html</guid><pubDate>Thu, 05 Mar 2009 14:32:00 +0200</pubDate><source>http://www.bizcommunity.com/rss/196/326.html</source></item><item><title>TLC and Cipla tell men The Bald Truth</title><link>http://www.bizcommunity.com/Article/196/326/33485.html</link><description>&lt;p&gt;Supplementing the launch of its anti-balding solution for men, the pharmaceutical giant, Cipla, has commissioned Primedia Unlimited subsidiary, The Letter Corporation, to run a month's advertising campaign in men's washrooms at Virgin Active and Planet Fitness gyms countrywide.&lt;br /&gt; &lt;a href="http://www.bizcommunity.com/Article/196/326/33485.html"&gt;Read full story...&lt;/a&gt; | &lt;a href="http://www.bizcommunity.com/SendToFriend.aspx?l=196&amp;c=326&amp;ct=1&amp;ci=33485"&gt;Send to a friend&lt;/a&gt;&lt;/p&gt;</description><guid>http://www.bizcommunity.com/Article/196/326/33485.html</guid><pubDate>Thu, 05 Mar 2009 13:56:00 +0200</pubDate><source>http://www.bizcommunity.com/rss/196/326.html</source></item><item><title>iNova pharmaceuticals launch new South African head office</title><link>http://www.bizcommunity.com/Article/196/326/33297.html</link><description>&lt;p&gt;&lt;img src="http://mars.bizcommunity.com/c/0903/26818.jpg?r=0" width="65" height="55" align="left"  /&gt;JOHANNESBURG: iNova Pharmaceuticals last week launched their new South African head office situated in Bedfordview, Johannesburg. iNova Pharmaceuticals country manager, Dr Irwin Juckes officially opened the offices at a red ribbon cutting ceremony  attended by iNova Pharmaceuticals directors based in Sydney,  Australia, local partners, stakeholders and the media.&lt;br /&gt; &lt;a href="http://www.bizcommunity.com/Article/196/326/33297.html"&gt;Read full story...&lt;/a&gt; | &lt;a href="http://www.bizcommunity.com/SendToFriend.aspx?l=196&amp;c=326&amp;ct=1&amp;ci=33297"&gt;Send to a friend&lt;/a&gt;&lt;/p&gt;</description><guid>http://www.bizcommunity.com/Article/196/326/33297.html</guid><pubDate>Mon, 02 Mar 2009 09:40:00 +0200</pubDate><source>http://www.bizcommunity.com/rss/196/326.html</source></item><item><title>Pfizer discontinues development of two phase two compounds</title><link>http://www.bizcommunity.com/Article/196/326/33168.html</link><description>&lt;p&gt;Pfizer Inc announced recently that, following a review of the development and commercial portfolios in the Primary Care Business Unit, it is terminating Phase 3 development programs for the investigational compounds esreboxetine for fibromyalgia and PD 332,334 for generalized anxiety disorder (GAD).&lt;br /&gt; &lt;a href="http://www.bizcommunity.com/Article/196/326/33168.html"&gt;Read full story...&lt;/a&gt; | &lt;a href="http://www.bizcommunity.com/SendToFriend.aspx?l=196&amp;c=326&amp;ct=1&amp;ci=33168"&gt;Send to a friend&lt;/a&gt;&lt;/p&gt;</description><guid>http://www.bizcommunity.com/Article/196/326/33168.html</guid><pubDate>Wed, 25 Feb 2009 11:40:00 +0200</pubDate><source>http://www.bizcommunity.com/rss/196/326.html</source></item></channel></rss>